Sleep deficits in mild cognitive impairment are related to increased levels of plasma amyloid-β and cortical thinning

NeuroImage

Volumn 98, Issue , 2014, Pages 395-404

  Sanchez Espinosa, Mayely P ^a   Atienza, Mercedes ^a   Cantero, Jose L ^a  

^a UNIVERSIDAD PABLO DE OLAVIDE   (Spain)

Author keywords

Alzheimer's disease; Cortical thickness; Mild cognitive impairment; Plasma amyloid beta; Sleep disturbances

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THINNING; DISEASE ASSOCIATION; ENTORHINAL CORTEX; FEMALE; GRAY MATTER; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM PARAMETERS; POSTCENTRAL GYRUS; POSTERIOR CINGULATE; PRECUNEUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REM SLEEP; SLEEP DISORDER; SLOW WAVE SLEEP; BLOOD; BRAIN CORTEX; COMPLICATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SLEEP;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; SLEEP; SLEEP DISORDERS; SLEEP, REM;

EID: 84903637959     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.05.027     Document Type: Article

References (118)

1. American Sleep Disorder Association EEG arousals: scoring rules and examples. Sleep 1992, 15:173-184.
2. Apostolova L.G., Steiner C.A., Akopyan G.G., Dutton R.A., Hayashi K.M., Toga A.W., Cummings J.L., Thompson P.M. Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease. Arch. Neurol. 2007, 64:1489-1495.
3. Araujo D.M., Lapchak P.A., Robitaille Y., Gauthier S., Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J. Neurochem. 1988, 50:1914-1923.
4. Arendt T., Bigl V., Tennstedt A., Arendt A. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer's disease. Neuroscience 1985, 14:1-14.
5. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666-669.
6. Bernal-Rusiel J.L., Atienza M., Cantero J.L. Detection of focal changes in human cortical thickness: spherical wavelets versus Gaussian smoothing. NeuroImage 2008, 41:1278-1292.
7. Bernal-Rusiel J.L., Atienza M., Cantero J.L. Determining the optimal level of smoothing in cortical thickness analysis: a hierarchical approach based on sequential statistical thresholding. NeuroImage 2010, 52:158-171.
8. Böhm P., Peña-Casanova J., Aguilar M., Hernandez G., Sol J.M., Blesa R., NORMACODEN Group Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities. Int. Psychogeriatr. 1998, 10:261-270.
9. Bombois S., Derambure P., Pasquier F., Monaca C. Sleep disorders in aging and dementia. J. Nutr. Health Aging 2010, 14:212-217.
10. Brun A., Englund E. Regional pattern of degeneration in Alzheimer's disease: neuronal loss and histopathological grading. Histopathology 1981, 5:549-564.
11. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J. Biol. Chem. 1992, 267:546-554.
12. Canessa N., Castronovo V., Cappa S.F., Aloia M.S., Marelli S., Falini A., Alemanno F., Ferini-Strambi L. Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment. Am. J. Respir. Crit. Care Med. 2011, 183:1419-1426.
13. Chafekar S.M., Zwart R., Veerhuis R., Vanderstichele H., Baas F., Scheper W. Increased Aβ1-42 production sensitizes neuroblastoma cells for ER stress toxicity. Curr. Alzheimer Res. 2008, 5:469-474.
14. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002, 13:1939-1943.
15. Chetelat G., Villemagne V.L., Pike K.E., Ellis K.A., Bourgeat P., Jones G., O'Keefe G.J., Salvado O., Szoeke C., Martins R.N., Ames D., Masters C.L., Rowe C.C., Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain 2011, 134:798-807.
16. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., Ashe K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8:79-84.
17. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. NeuroImage 1999, 9:179-194.
18. Desikan R.S., Sabuncu M.R., Schmansky N.J., Reuter M., Cabral H.J., Hess C.P., Weiner M.W., Biffi A., Anderson C.D., Rosand J., Salat D.H., Kemper T.L., Dale A.M., Sperling R.A., Fischl B., Alzheimer's Disease Neuroimaging Initiative Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One 2010, 5(9):e12853.
19. Driscoll I., Davatzikos C., An Y., Wu X., Shen D., Kraut M., Resnick S.M. Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology 2009, 72:1906-1913.
20. Driscoll I., Troncoso J.C., Rudow G., Sojkova J., Pletnikova O., Zhou Y., Kraut M.A., Ferrucci L., Mathis C.A., Klunk W.E., O'Brien R.J., Davatzikos C., Wong D.F., Resnick S.M. Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol. 2012, 124:823-831.
21. Drzezga A., Becker J.A., Van Dijk K.R., Sreenivasan A., Talukdar T., Sullivan C., Schultz A.P., Sepulcre J., Putcha D., Greve D., Johnson K.A., Sperling R.A. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain 2011, 134:1635-1646.
22. Fazekas F., Chawluk J.B., Alavi A., Hurtig H.I., Zimmerman R.A. MR signal abnormalities at 1.5T in Alzheimer's dementia and normal aging. Am. J. Roentgenol. 1987, 149:351-356.
23. Fei M., Jianghua W., Rujuan M., Wei Z., Qian W. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment. J. Neurol. Sci. 2011, 305:92-96.
24. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11050-11055.
25. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. NeuroImage 1999, 9:195-207.
26. Fischl B., Sereno M.I., Tootell R.B., Dale A.M. High-resolution intersubject averaging and a coordinate system for the cortical surface. Hum. Brain Mapp. 1999, 8:272-284.
27. Fischl B., Liu A., Dale A.M. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans. Med. Imaging 2001, 20:70-80.
28. Fjell A.M., Walhovd K.B., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Holland D., Brewer J.B., Dale A.M., Alzheimer's Disease Neuroimaging Initiative CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J. Neurosci. 2010, 30:2088-2101.
29. Forman M.S., Mufson E.J., Leurgans S., Pratico D., Joyce S., Leight S., Lee V.M., Trojanowski J.Q. Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology 2007, 68:757-763.
30. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långström B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1456-1465.
31. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 2003, 60:958-964.
32. Geda Y.E., Smith G.E., Knopman D.S., Boeve B.F., Tangalos E.G., Ivnik R.J., Mrazek D.A., Edland S.D., Petersen R.C. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int. Psychogeriatr. 2004, 16:51-60.
33. Geula C., Mesulam M.M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience 1989, 33:469-481.
34. Giess R., Schlote W. Localisation and association of pathomorphological changes at the brainstem in Alzheimer's disease. Mech. Ageing Dev. 1995, 84:209-226.
35. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., Hyman B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996, 16:4491-4500.
36. Goñi J., Cervantes S., Arrondo G., Lamet I., Pastor P., Pastor M.A. Selective brain gray matter atrophy associated with APOE ε4 and MAPT H1 in subjects with mild cognitive impairment. J. Alzheimers Dis. 2013, 33:1009-1019.
37. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 2007, 64:354-362.
38. Greyer S., Schleicher A., Zilles K. Areas 3a, 3b, and 1 of human primary somatosensory cortex. NeuroImage 1999, 10:63-83.
39. Grothe M., Zaborszky L., Atienza M., Gil-Neciga E., Rodriguez-Romero R., Teipel S.J., Amunts K., Suarez-Gonzalez A., Cantero J.L. Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer's disease. Cereb. Cortex 2010, 20:1685-1695.
40. Hampel H., Wilcock G., Andrieu S., Aisen P., Blennow K., Broich K., Carrillo M., Fox N.C., Frisoni G.B., Isaac M., Lovestone S., Nordberg A., Prvulovic D., Sampaio C., Scheltens P., Weiner M., Winblad B., Coley N., Vellas B., Oxford Task Force Group Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2011, 95:579-593.
41. Hänggi J., Streffer J., Jäncke L., Hock C. Volumes of lateral temporal and parietal structures distinguish between healthy aging, mild cognitive impairment, and Alzheimer's disease. J. Alzheimers Dis. 2011, 26:719-734.
42. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31:357-367.
43. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
44. Haroutunian V., Perl D.P., Purohit D.P., Marin D., Khan K., Lantz M., Davis K.L., Mohs R.C. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch. Neurol. 1998, 55:1185-1195.
45. Herukka S.K., Pennanen C., Soininen H., Pirttilä T. CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J. Alzheimers Dis. 2008, 14:51-57.
46. Hita-Yañez E., Atienza M., Gil-Neciga E., Cantero J.L. Disturbed sleep patterns in elders with mild cognitive impairment: the role of memory decline and ApoE ε4 genotype. Curr. Alzheimer Res. 2012, 9:290-297.
47. Hita-Yañez E., Atienza M., Cantero J.L. Polysomnographic and subjective sleep markers of mild cognitive impairment. Sleep 2013, 36:1327-1334.
48. Huang Y., Potter R., Sigurdson W., Santacruz A., Shih S., Ju Y.E., Kasten T., Morris J.C., Mintun M., Duntley S., Bateman R.J. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch. Neurol. 2012, 69:51-58.
49. Hughes C.P., Berg L., Danzier W.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
50. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of Abeta 42(43) and Abeta 40 in senile plaques with end-specific Abeta monoclonals: evidence that an initially deposited species is Abeta 42(43). Neuron 1994, 13:45-53.
51. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991, 14:540-545.
52. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
53. Kemppainen N.M., Aalto S., Wilson I.A., Någren K., Helin S., Brück A., Oikonen V., Kailajärvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
54. Kim I., Xu W., Reed J.C. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 2008, 7:1013-1030.
55. Koyama A., Okereke O.I., Yang T., Blacker D., Selkoe D.J., Grodstein F. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch. Neurol. 2012, 69:824-831.
56. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., Van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60:878-888.
57. Lee K.S., Cho H.S., Hong C.H., Kim D.G., Oh B.H. Differences in neuropsychiatric symptoms according to mild cognitive impairment subtypes in the community. Dement. Geriatr. Cogn. Disord. 2008, 26:212-217.
58. Lobo A., Escoba V., Exquerra J., Sevar-Diaz A. Mini-Examen Cognoscitivo: Un test sencillo, práctico, para detectar alteraciones intelectuales en pacientes psiquiátricos. Actas Luso Esp. Neurol. Psiquiatr. Cienc. Afines 1979, 3:189-202.
59. Loewenstein R.J., Weingartner H., Gillin J.C., Kaye W., Ebert M., Mendelson W.B. Disturbances of sleep and cognitive functioning in patients with dementia. Neurobiol. Aging 1982, 3:371-377.
60. London E.D., Ball M.J., Waller S.B. Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia. Neurochem. Res. 1989, 14:745-750.
61. Macey P.M., Henderson L.A., Macey K.E., Alger J.R., Frysinger R.C., Woo M.A., Harper R.K., Yan-Go F.L., Harper R.M. Brain morphology associated with obstructive sleep apnea. Am. J. Respir. Crit. Care Med. 2002, 166:1382-1387.
62. Makela K.A., Wigren H.K., Zant J.C., Sakurai T., Alhonen L., Kostin A., Porkka-Heiskanen T., Herzig K.H. Characterization of sleep-wake patterns in a novel transgenic mouse line overexpressing human prepro-orexin/hypocretin. Acta Physiol. (Oxf.) 2010, 198:237-249.
63. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61:1185-1190.
64. McDonald B., Highley J.R., Walker M.A., Herron B.M., Cooper S.J., Esiri M.M., Crow T.J. Anomalous asymmetry of fusiform and parahipocampal gyrus gray matter in schizophrenia: A postmortem study. Am. J. Psychiatry 2000, 157:40-47.
65. McGeer P.L., McGeer E.G., Suzuki J., Dolman C.E., Nagai T. Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain. Neurology 1984, 34:741-745.
66. Mesulam M.M., Geula C. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase. J. Comp. Neurol. 1988, 275:216-240.
67. Mieda M., Willie J.T., Hara J., Sinton C.M., Sakurai T., Yanagisawa M. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4649-4654.
68. Moe K.E., Vitiello M.V., Larsen L.H., Prinz P.N. Cognitive processes and sleep disturbances: Sleep/wake patterns in Alzheimer's disease: relationships with cognition and function. J. Sleep Res. 1995, 4:15-20.
69. Morbelli S., Piccardo A., Villavecchia G., Dessi B., Brugnolo A., Piccini A., Caroli A., Frisoni G., Rodriguez G., Nobili F. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur. J. Nucl. Med. Mol. 2010, 37:36-45.
70. Mufson E.J., Mash D.C., Hersh L.B. Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann. Neurol. 1988, 24:623-629.
71. Naidoo N. Roles of endoplasmic reticulum and energetic stress in disturbed sleep. Neuromolecular Med. 2012, 14:213-219.
72. Naidoo N., Ferber M., Master M., Zhu Y., Pack A.I. Aging impairs the unfolded protein response to sleep deprivation and leads to proapoptotic signaling. J. Neurosci. 2008, 28:6539-6548.
73. Naidoo N., Zhu J., Zhu Y., Fenik P., Lian J., Galante R., Veasey S. Endoplasmic reticulum stress in wake-active neurons progresses with aging. Aging Cell 2011, 10:640-649.
74. Nishitsuji K., Tomiyama T., Ishibashi K., Ito K., Teraoka R., Lambert M.P., Klein W.L., Mori H. The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid β oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am. J. Pathol. 2009, 174:957-969.
75. Pavlova M.K., Duffy J.F., Shea S.A. Polysomnographic respiratory abnormalities in asymptomatic individuals. Sleep 2008, 31:241-248.
76. Pengas G., Hodges J.R., Watson P., Nestor P.J. Focal posterior cingulate atrophy in incipient Alzheimer's disease. Neurobiol. Aging 2010, 31:25-33.
77. Petersen P.R., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
78. Prinz P.N., Vitaliano P.P., Vitiello M.V., Bokan J., Raskind M., Peskind E., Gerber C. Sleep, EEG and mental function changes in senile dementia of the Alzheimer's type. Neurobiol. Aging 1982, 3:361-370.
79. Rechtschaffen A., Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects 1968, UCLA Brain Information Service/Brain Research Institute, Los Angeles, California.
80. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 2011, 7:137-152.
81. Rissman R.A., Trojanowski J.Q., Shaw L.M., Aisen P.S. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J. Neural Transm. 2012, 119:843-850.
82. Roh J.H., Huang Y., Bero A.W., Kasten T., Stewart F.R., Bateman R.J., Holtzman D.M. Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci. Transl. Med. 2012, 4. (150ra122).
83. Roher A.E., Maarouf C.L., Sue L.I., Hu Y., Wilson J., Beach T.G. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009, 14:493-501.
84. Rosas H.D., Liu A.K., Hersch S., Glessner M., Ferrante R.J., Salat D.H., van der Kouwe A., Jenkins B.G., Dale A.M., Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 2002, 58:695-701.
85. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
86. Sabbagh M.N., Cooper K., DeLange J., Stoehr J.D., Thind K., Lahti T., Reisberg B., Sue L., Vedders L., Fleming S.R., Beach T.G. Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr. Alzheimer Res. 2010, 7:280-286.
87. Salat D.H., Buckner R.L., Snyder A.Z., Greve D.N., Desikan R.S., Busa E., Morris J.C., Dale A.M., Fischl B. Thinning of the cerebral cortex in aging. Cereb. Cortex 2004, 14:721-730.
88. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
89. Scheperjans F., Eickhoff S.B., Hömke H., Mohlberg K., Hermann K., Amunts K., Zilles K. Probabilistic maps, morphometry, and variability of citoarchitectonic areas in the human superior parietal cortex. Cereb. Cortex 2008, 18:2141-2157.
90. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14052-14057.
91. Segonne F., Dale A.M., Busa E., Glessner M., Salat D., Hahn H.K., Fischl B. A hybrid approach to the skull stripping problem in MRI. NeuroImage 2004, 22:1060-1075.
92. Selkoe D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 1994, 17:489-517.
93. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
94. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J. Neurochem. 1986, 46:288-293.
95. Spulber G., Niskanen E., Macdonald S., Kivipelto M., Padilla D.F., Julkunen V., Hallikainen M., Vanninen R., Wahlund L.O., Soininen H. Evolution of global and local grey matter atrophy on serial MRI scans during the progression from MCI to AD. Curr. Alzheimer Res. 2012, 9:516-524.
96. Stephan A., Laroche S., Davis S. Generation of aggregated beta-amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J. Neurosci. 2001, 21:5703-5714.
97. Takahashi K., Niidome T., Akaike A., Kihara T., Sugimoto H. Amyloid precursor protein promotes endoplasmic reticulum stress-induced cell death via C/EBP homologous protein-mediated pathway. J. Neurochem. 2009, 109:1324-1337.
98. Takeda S., Sato N., Rakugi H., Morishita R. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol. Biosyst. 2010, 6:1760-1766.
99. Teipel S.J., Meindl T., Grinberg L., Grothe M., Cantero J.L., Reiser M.F., Möller H.J., Heinsen H., Hampel H. The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. Hum. Brain Mapp. 2011, 32:1349-1362.
100. Terry R.D., Katzman R. Senile dementia of the Alzheimer type. Ann. Neurol. 1983, 14:497-506.
101. Thakkar M., Portas C., McCarley R.W. Chronic low-amplitude electrical stimulation of the laterodorsal tegmental nucleus of freely moving cats increases REM sleep. Brain Res. 1996, 723:223-227.
102. Tranah G.J., Blackwell T., Stone K.L., Ancoli-Israel S., Paudel M.L., Ensrud K.E., Cauley J.A., Redline S., Hillier T.A., Cummings S.R., Yaffe K., SOF Research Group Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann. Neurol. 2011, 70:722-732.
103. Umeda T., Tomiyama T., Sakama N., Tanaka S., Lambert M.P., Klein W.L., Mori H. Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J. Neurosci. Res. 2011, 89:1031-1042.
104. Van Essen D.C., Drury H.A., Joshi S., Miller M.I. Functional and structural mapping of human cerebral cortex: solutions are in the surfaces. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:788-795.
105. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-660.
106. Vemuri P., Wiste H.J., Weigand S.D., Shaw L.M., Trojanowski J.Q., Weiner M.W., Knopman D.S., Petersen R.C., Jack C.R. Alzheimer's disease neuroimaging initiative. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009, 73:287-293.
107. Vitiello M.V., Prinz P.N., Williams D.E., Frommlet M.S., Ries R.K. Sleep disturbances in patients with mild-stage Alzheimer's disease. J. Gerontol. 1990, 45:131-138.
108. Vogels O.J., Broere C.A., ter Laak H.J., ten Donkelaar H.J., Nieuwenhuys R., Schulte B.P. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol. Aging 1990, 11:3-13.
109. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
110. Webster H.H., Jones B.E. Neurotoxic lesions of the dorsolateral pontomesencephalic tegmentum-cholinergic cell area in the cat. II. Effects upon sleep-waking states. Brain Res. 1988, 458:285-302.
111. Wechsler D. WMS-III. Wechsler Memory Scale-III: Application and scoring manual. Madrid, TEA Ediciones 2004.
112. Westerberg C.E., Mander B.A., Florczak S.M., Weintraub S., Mesulam M.M., Zee P.C., Paller K.A. Concurrent impairments in sleep and memory in amnestic mild cognitive impairment. J. Int. Neuropsychol. Soc. 2012, 18:490-500.
113. Whitehouse P.J., Price D.L., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981, 10:122-126.
114. Whitwell J.L., Przybelski S.A., Weigand S.D., Knopman D.S., Boeve B.F., Petersen R.C., Jack C.R. 3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain 2007, 130:1777-1786.
115. Xie L., Kang H., Xu Q., Chen M.J., Liao Y., Thiyagarajan M., O'Donnell J., Christensen D.J., Nicholson C., Iliff J.J., Takano T., Deane R., Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
116. Yaffe K., Laffan A.M., Harrison S.L., Redline S., Spira A.P., Ensrud K.E., Ancoli-Israel S., Stone K.L. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. J. Am. Med. Assoc. 2011, 306:613-619.
117. Yesavage J.A., Brink T.L., Rose T.L., Lum O. Development and validation of a geriatric depression scale: a preliminary report. J. Psychiatry Res. 1983, 17:37-49.
118. Zhou B., Liu Y., Zhang Z., An N., Yao H., Wang P., Wang L., Zhang X., Jiang T. Impaired functional connectivity of the thalamus in Alzheimer' s disease and mild cognitive impairment: a resting-state FMRI study. Curr. Alzheimer Res. 2013, 10:754-766.